, .ck_form input[type="email"] { font-size: 14px; padding: 10px 8px; width: 100%; border: 1px solid #d6d6d6; /* stroke */ -moz-border-radius: 4px; -webkit-border-radius: 4px; border-radius: 4px; /* border radius */ background-color: #f8f7f7; /* layer fill content */ margin-bottom: 5px; height: auto; } .ck_form input[type="text"]:focus, .ck_form input[type="email"]:focus { outline: none; border-color: #aaa; } .ck_checkbox { padding: 10px 0px 10px 20px; display: block; clear: both; } .ck_checkbox input.optIn { margin-left: -20px; margin-top: 0; } .ck_form .ck_opt_in_prompt { margin-left: 4px; } .ck_form .ck_opt_in_prompt p { display: inline; } .ck_form .ck_subscribe_button { width: 100%; color: #fff; margin: 10px 0px 0px; padding: 10px 0px; font-size: 18px; background: #0d6db8; -moz-border-radius: 4px; -webkit-border-radius: 4px; border-radius: 4px; /* border radius */ cursor: pointer; border: none; text-shadow: none; } .ck_form .ck_guarantee { color: #626262; font-size: 12px; text-align: center; padding: 5px 0px; display: block; } .ck_form .ck_powered_by { display: block; color: #aaa; } .ck_form .ck_powered_by:hover { display: block; color: #444; } .ck_converted_content { display: none; padding: 5%; background: #fff; } /* v6 */ .ck_form_v6 #ck_success_msg { padding: 0px 10px; } @media all and (max-width: 403px) { .ck_form_v6.ck_modal .ck_close_link { top: 30px; } } @media all and (min-width: 404px) and (max-width: 499px) { .ck_form_v6.ck_modal .ck_close_link { top: 57px; } } " rev_name="Tabula Rasa Healthcare IPO Notes" rev_body="

Tabula Rasa (TRHC) is a healthcare service provider with ~25% sustainable growth in recurring revenue, expanding gross margins and a model that is very likely to generate 20% EBITDA margins over the long term.

As you can see from the company snapshot growth is healthy. With 16.1M shares outstanding post-IPO the market capitalization is $241M at $15/share which is the upper end of the proposed price range.

The core of what TRHC does is prevent nasty drug interactions in patients. There's a lot to take into account, especially since many patients, especially older ones, can be on over a dozen medications. As more factors are added to the analysis the problem gets harder to manage. It's no wonder organizations are happy to outsource this to a service provider like TRHC.

Given a market capitalization of $240M and probable sales of about $90M this year that's a P/S ratio of 2.7x. It's also around 13x normalized adjusted EBITDA. The IPO is already said to be well-subscribed and likely to price at or above the high end of the range. Given the growth, recurring revenue, competitive position and margins we'd see this with a 25x multiple.

We've used a new "Quick and Dirty Intrinsic Value QDIV" model to estimate that TRHC could double from the IPO price.

Once the transcript is completed we will post a link here.

 

 

" author="Candyman" pubdate='2016-09-28' ]